ValiFinn Buys Pharmatest Services' Biomarker Business | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ValiRx today announced its wholly owned subsidiary ValiFinn has bought the biomarkers business of Pharmatest Services for €75,000 ($96,000) plus stock.

The purchase includes five patent families and patent applications and related intellectual property. Pharmatest, based in Finland, also received 15 million shares of ValiRx stock at a price of .52 pence per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.